These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 20467289)

  • 41. Estimation of mortality among HIV-infected people on antiretroviral treatment in East Africa: a sampling based approach in an observational, multisite, cohort study.
    Geng EH; Odeny TA; Lyamuya RE; Nakiwogga-Muwanga A; Diero L; Bwana M; Muyindike W; Braitstein P; Somi GR; Kambugu A; Bukusi EA; Wenger M; Wools-Kaloustian KK; Glidden DV; Yiannoutsos CT; Martin JN
    Lancet HIV; 2015 Mar; 2(3):e107-16. PubMed ID: 26424542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adult life expectancy trends in the era of antiretroviral treatment in rural Uganda (1991-2012).
    Asiki G; Reniers G; Newton R; Baisley K; Nakiyingi-Miiro J; Slaymaker E; Kasamba I; Seeley J; Todd J; Kaleebu P; Kamali A
    AIDS; 2016 Jan; 30(3):487-93. PubMed ID: 26765939
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Study on the mortality and risk factors among HIV/AIDS patients receiving antiretroviral therapy in Xinjiang Uygur Autonomous Region].
    Ni M; Chen X; Hu X; Ma Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Nov; 48(11):953-8. PubMed ID: 25582364
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mortality associated with HIV-1 infection over five years in a rural Ugandan population: cohort study.
    Nunn AJ; Mulder DW; Kamali A; Ruberantwari A; Kengeya-Kayondo JF; Whitworth J
    BMJ; 1997 Sep; 315(7111):767-71. PubMed ID: 9345167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.
    Pujades-Rodríguez M; Balkan S; Arnould L; Brinkhof MA; Calmy A;
    JAMA; 2010 Jul; 304(3):303-12. PubMed ID: 20639564
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata.
    Palella FJ; Deloria-Knoll M; Chmiel JS; Moorman AC; Wood KC; Greenberg AE; Holmberg SD;
    Ann Intern Med; 2003 Apr; 138(8):620-6. PubMed ID: 12693883
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Secular trends in the survival of HIV-infected homosexual men in Amsterdam and Vancouver estimated from a death-included CD4-staged Markov model.
    Hendriks JC; Craib KJ; Veugelers PJ; van Druten HA; Coutinho RA; Schechter MT; van Griensven GJ
    Int J Epidemiol; 2000 Jun; 29(3):565-72. PubMed ID: 10869332
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Health-adjusted life expectancy in HIV-positive and HIV-negative men and women in British Columbia, Canada: a population-based observational cohort study.
    Hogg RS; Eyawo O; Collins AB; Zhang W; Jabbari S; Hull MW; Lima VD; Ahmed T; Kendall CE; Althoff KN; Justice AC; Barrios R; Shoveller J; Montaner JSG;
    Lancet HIV; 2017 Jun; 4(6):e270-e276. PubMed ID: 28262574
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Survival analysis on HIV/AIDS patients who began receiving antiretroviral therapy from 2005 to 2015 in Tianjin].
    Guo Y; Zhou N; Zhao FN; Liu ZQ; Li L; Yu MH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Aug; 40(8):936-940. PubMed ID: 31484257
    [No Abstract]   [Full Text] [Related]  

  • 50. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count.
    García F; de Lazzari E; Plana M; Castro P; Mestre G; Nomdedeu M; Fumero E; Martínez E; Mallolas J; Blanco JL; Miró JM; Pumarola T; Gallart T; Gatell JM
    J Acquir Immune Defic Syndr; 2004 Jun; 36(2):702-13. PubMed ID: 15167289
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.
    Helleberg M; Kronborg G; Larsen CS; Pedersen G; Pedersen C; Obel N; Gerstoft J
    HIV Med; 2013 Jul; 14(6):362-9. PubMed ID: 23433434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Do people with HIV infection have a normal life expectancy in the era of combination antiretroviral therapy?
    Sabin CA
    BMC Med; 2013 Nov; 11():251. PubMed ID: 24283830
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Survival analysis of HIV/AIDS patients with access to highly antiretroviral therapy in Ningbo during 2004-2015].
    Zhang JH; Li HL; Shi HB; Jiang HB; Hong H; Dong HJ
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Sep; 37(9):1262-1267. PubMed ID: 27655575
    [No Abstract]   [Full Text] [Related]  

  • 55. Outcomes of the Botswana national HIV/AIDS treatment programme from 2002 to 2010: a longitudinal analysis.
    Farahani M; Vable A; Lebelonyane R; Seipone K; Anderson M; Avalos A; Chadborn T; Tilahun H; Roumis D; Moeti T; Musuka G; Busang L; Gaolathe T; Malefho KC; Marlink R
    Lancet Glob Health; 2014 Jan; 2(1):e44-50. PubMed ID: 25104635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time to initiate antiretroviral therapy between 4 weeks and 12 weeks of tuberculosis treatment in HIV-infected patients: results from the TIME study.
    Manosuthi W; Mankatitham W; Lueangniyomkul A; Thongyen S; Likanonsakul S; Suwanvattana P; Thawornwan U; Suntisuklappon B; Nilkamhang S; Sungkanuparph S;
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):377-83. PubMed ID: 22592586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016.
    Marcus JL; Leyden WA; Alexeeff SE; Anderson AN; Hechter RC; Hu H; Lam JO; Towner WJ; Yuan Q; Horberg MA; Silverberg MJ
    JAMA Netw Open; 2020 Jun; 3(6):e207954. PubMed ID: 32539152
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population.
    Jensen-Fangel S; Pedersen L; Pedersen C; Larsen CS; Tauris P; Møller A; Sørensen HT; Obel N
    AIDS; 2004 Jan; 18(1):89-97. PubMed ID: 15090834
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [A retrospective cohort study on survival time of AIDS death cases receiving Antiretroviral Therapy and related factors].
    Hao L; Zhu X; Wang G; Lin B; Qian Y; Tao X; Hu J; Yang X; Kang D
    Zhonghua Yu Fang Yi Xue Za Zhi; 2014 Jun; 48(6):466-70. PubMed ID: 25219434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Factors associated with long-term CD4 cell recovery in HIV-infected patients on successful antiretroviral therapy.
    Collazos J; Valle-Garay E; Carton JA; Montes AH; Suarez-Zarracina T; De la Fuente B; Asensi V
    HIV Med; 2016 Aug; 17(7):532-41. PubMed ID: 26754349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.